Louvain-la-Neuve, Belgium, 18 February, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will host a Capital Markets Day (CMD) for investors and analysts on Monday 7 April 2025 at 2pm CET / 1pm GMT / 8am ET.
The event will include presentations, panel discussions and Q&A sessions led by IBA’s management team with speakers from across the Group. Attendees will have the opportunity to gain valuable insights into IBA’s strategy, including selected growth initiatives and performance drivers, as well as a deep dive into its business lines and markets.
For further information, please contact ICR Healthcare IBA@icrhealthcare.com.
***ENDS***
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
CONTACTS
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
ICR Healthcare
Amber Fennell, Angela Gray, Lucy Featherstone
+44 (0) 20 3709 5700
IBA@icrhealthcare.com
Attachment
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。